A GLP-1 weight-loss plateau can happen when your body adapts, calorie intake shifts, protein drops, movement changes, or dosing needs reassessment. A plateau does not mean the medication stopped working; it usually means the plan needs refinement.
The first month of medical weight loss usually focuses on evaluation, baseline habits, dosing, side-effect prevention, hydration, protein, and realistic expectations. Progress is individual, and a supportive plan matters as much as the medication.
Semaglutide and tirzepatide are injectable medications that support appetite regulation and weight loss, but tirzepatide acts on both GLP-1 and GIP pathways while semaglutide focuses on GLP-1. The best option depends on health history, response, tolerance, and provider guidance.